GVHD: Overview on pathophysiology, incidence, clinical and biological features

Bone Marrow Transplantation

Volumn 21, Issue SUPPL. 2, 1998, Pages

  Klingebiel, T ^a   Schlegel, P G ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bone marrow transplantation; Clinical features; Graft versus host disease; Incidence biology; Pathophysiology

Indexed keywords

CELL ADHESION MOLECULE; CYCLOSPORIN A; CYTOKINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ALLOGENIC BONE MARROW TRANSPLANTATION; CHILD; CLINICAL FEATURE; CONFERENCE PAPER; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; BONE MARROW TRANSPLANTATION; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS; INCIDENCE; T-LYMPHOCYTES;

EID: 0031949425     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Hathaway WE, Githens JH, Blackburn WR et al. Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children: probable human runt disease. N Engl J Med 1965; 273: 953-958.
2. Billingham RE. The biology of graft-versus-host reactions. In: The Harvey Lectures. Academic Press, New York, 1966; Vol 62, pp. 21-78.
3. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED. (eds.) Bone marrow transplantation Blackwell Scientific Publications: Oxford, 1994, pp. 339-362.
4. Ferrara JLM, Deeg HJ. Graft-versus-host diesease. N Engl J Med 1991; 324: 667-674.
5. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765-771.
6. Speiser DE, Tiercy JM, Rufer N et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87: 4455-4462.
7. Chao NJ. GVHD: the viewpoint from the donor T cell. Biol Blood Marrow Transplant 1997; 3: 1-10.
8. Schlegel PG, Aharoni R, Smilek DE et al. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994; 84: 2802-2810.
9. Schlegel PG, Aharoni R, Chen Y et al. A synthetic random basic copolymer with promiscuous binding to murine class II MHC molecules inhibits T cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-vs-host disease in vivo. Proc Natl Acad Sci USA 1996; 93: 5061-5066.
10. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-285.
11. Hill GR, Crawford JM, Cooke KR et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
12. Ferrara JL. Cytokine inhibitors and graft-versus-host disease. Ann N Y Acad Sc 1995; 770: 227-236.
13. Rus V, Svetic A, Nguyen P et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol 1995; 155: 2396-2406.
14. Körholz D, Hempel L, Packeisen J et al. Significance of interleukin 10 for acute graft-versus-host disease in children and adolescents after allogenic bone marrow transplantation. Klin Padiatr 1996: 208: 141-144.
15. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin-10. Ann Med 1995; 27: 537-541.
16. Locatelli F, Pession A, Zecca M et al. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant 1996; 17: 31-37.
17. Sykes M, Harty MW, Szot GL, Pearson DA. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 1994; 83: 2560-2569.
18. Holler E, Kolb HJ, Mittermuller J et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF-α) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890-899.
19. Blazar BR, Taylor PA, Gray GS et al. The role of T cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or multiple minor histocompatibility-disparate donor inocula. Transplantation 1994; 58: 1422-1426.
20. Schlegel PG. The role of adhesion and costimulation molecules in GVHD. Acta Haematol 1997; 97: 105-117.
21. Hagglund H, Bostrom L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747-753.
22. Winiarski J, Ringden O, Remberger M et al. Bone marrow transplantation in children using unrelated donors at Huddinge Hospital. Acta Paediatr 1996; 85: 327-335.
23. Balduzzi A, Gooley T, Anasetti C et al. Unrelated donor marrow transplantation in children. Blood 1995; 86: 3247-3256.
24. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukemia in second complete remission. Br J Haematol 1996; 94: 574-578.
25. Klingebiel T, Schumm M, Lang, P et al. CD34 enrichment as GVHD prophylaxis in mismatched related and unrelated bone marrow transplantation. Blood 1997; 90 (suppl. 1): 397b (abs).
26. Kurtzberg J, Laughlin M. Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157-166.